Croft S A, Daly M E, Steeds R P, Channer K S, Samani N J, Hampton K K
Division of Molecular and Genetic Medicine, University of Sheffield, Royal Hallamshire Hospital, UK.
Thromb Haemost. 1999 Jun;81(6):861-4.
The relationship between the prothrombin (PT) 20210A allele and arterial disease is controversial. We conducted a case-control study to assess its contribution to risk of myocardial infarction (MI). Five hundred and thirty-nine acute MI patients and 498 control subjects aged <75 years were studied. Two percent of cases carried the PT20210A allele compared to 2.8% of controls. The odds ratio for MI was 0.72 (95% CI 0.32-1.60) indicating that the PT20210A allele confers no increased risk for MI. Subgroup analysis showed no association between the PT20210A allele and either premature MI or MI in females. We conclude the PT20210A allele is not a risk factor for MI and suggest that discrepancies in studies relating the PT20210A allele to MI may be due to difficulties in estimating its low allelic frequency in the general population and thus random differences in the observed frequencies in the control populations studied.
凝血酶原(PT)20210A等位基因与动脉疾病之间的关系存在争议。我们进行了一项病例对照研究,以评估其对心肌梗死(MI)风险的影响。研究了539例年龄小于75岁的急性心肌梗死患者和498例对照受试者。2%的病例携带PT20210A等位基因,而对照组为2.8%。心肌梗死的优势比为0.72(95%可信区间0.32 - 1.60),表明PT20210A等位基因不会增加心肌梗死风险。亚组分析显示,PT20210A等位基因与女性早发性心肌梗死或心肌梗死之间均无关联。我们得出结论,PT20210A等位基因不是心肌梗死的危险因素,并认为将PT20210A等位基因与心肌梗死相关的研究差异可能是由于难以估计其在一般人群中的低等位基因频率,以及因此在所研究的对照人群中观察到的频率存在随机差异所致。